<DOC>
	<DOCNO>NCT01332383</DOCNO>
	<brief_summary>To investigate long-term safety efficacy AMERGE ( naratriptan hydrochloride ) Japanese patient migraine headache clinical setting</brief_summary>
	<brief_title>Special Drug Use Investigation AMERGEÂ® Tablet ( Long-term )</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naratriptan</mesh_term>
	<criteria>Must use AMERGE first time Patients hypersensitivity naratriptan component . Patients history , symptom , sign myocardial infarction , ischemic cardiac angina inversa Patients history cerebral vascular disturbance transient ischaemic attack Patients peripheral vascular syndrome Patients uncontrolled hypertension Patients severe renal hepatic impairment Patients use treatment another 5HT1 agonist , ergotaminecontaining ergottype medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>